Navigation Links
Enbrel® (etanercept) Patent Issued
Date:11/22/2011

THOUSAND OAKS, Calif., Nov. 22, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today issued the following statement:

Amgen today announced  the issuance of U.S. Patent No. 8,063,182 related to Enbrel® (etanercept).  This patent is owned by Hoffman-La Roche Inc. ("Roche") and exclusively licensed to Amgen. Immunex Corporation (acquired by Amgen in 2002) originally licensed this patent application from Roche in 1999, and in 2004, Amgen paid Roche a one-time payment and obtained an exclusive, fully paid-up license to the application which issued today as the '182  patent.  The patent describes and claims the fusion protein that is etanercept, and by statute, the '182 patent has a term of 17 years from today.

About ENBREL
ENBREL is a soluble form of a fully human tumor necrosis factor (TNF) receptor with a clinical efficacy and safety profile established over 18 years of collective clinical experience. ENBREL was first approved in the U.S. in 1998 for moderate to severe rheumatoid arthritis and was later approved to treat children and adolescents with moderate to severe juvenile rheumatoid arthritis (now called juvenile idiopathic arthritis) in 1999. In 2004, ENBREL was approved in the U.S. to treat adult chronic moderate to severe plaque psoriasis. Prescription ENBREL is given by injection.

ENBREL indications in the U.S.:

  • ENBREL is indicated for reducing signs and symptoms, keeping joint damage from getting worse and improving physical function in patients with moderate to severe rheumatoid arthritis. ENBREL can be taken with methotrexate or used alone.
  • ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in children ages 2 years and older.
  • ENBREL is indicated for reducing signs and symptoms,
    '/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vermillion Receives Notice of Allowance for 5th Biomarker Patent Related to Peripheral Artery Disease
2. Epitomics, Inc. Receives Notice of Allowance from the United States Patent and Trademark Office for a Novel Method for Identifying Differentially Expressed Proteins
3. iBio Announces New US Patent for iBioLaunch™ Technology
4. NuMe Health Advances its Cobiotics™ Technology With Addition of Scientific Advisory Board and Filing of Patent Application for First Product
5. Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
6. KGI Professor Awarded Patent for Stem-Cell Therapy Aiding Heart-attack Patients
7. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
8. Cenestra Health Issued Notice of Allowance: Expands Patent Range of High-Purity Omega-3 Fatty Acid Formulations
9. Life Technologies Applauds Signing of Patent Reform Bill
10. MedWaves, Incorporated Announces Receipt of the Chinese State Food and Drug Administration (SFDA) Certification to Import and Sell Its Patented AveCure™ Microwave Ablation System and Devices
11. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... regenerative medicine, today announced that it will release fourth ... on Tuesday, March 10, 2015 after the close of ... conference call and webcast on Tuesday, March 10, 2015 ... discuss the results and recent corporate developments. ...
(Date:3/2/2015)... 02, 2015 Global Stem ... alliance with Shenzhen HANK Bioengineering Co., Ltd. and ... alliance will establish a stem cells training course ... in September 2015. , Shenzhen HANK is a ... award-winning scientist, microbiologist and virologist, to integrate research, ...
(Date:2/28/2015)... Increasing its efforts to resolve the GMO Controversy ... of The GMO TRUTH podcast on both ITunes and at ... its mission to discover the truth and change the world. ... the truth about the GMOs in our food supply,” adds ... is an expansion of the documentary/investigative film-making methodology in place ...
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... toxicology studies for its newly developed Bruton,s tyrosine ... have been completed. The results of these preclinical ... and Drug Administration. The feedback received from the ... ongoing first-in-human study. Additional preclinical work is required ...
Breaking Biology Technology:Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2014 Results on March 10, 2015 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3
... Pharmaceuticals Inc. (Nasdaq: VNDA ), a biopharmaceutical ... product candidates for central nervous system disorders, today announced ... March 31, 2009. Vanda reported a net loss ... compared to $7.5 million for the fourth quarter of ...
... Mass., April 29 LaVoie Group, a life ... has been selected as public relations agency of ... Inc. Donna L. LaVoie, President & CEO of ... Profectus during an important stage in the company,s ...
... billions in pest losses annually , ... St. Louis, MO (PRWEB) April ... Divergence, Inc. , has received more than $1.2 million in research grants, ... to further the company,s work on biotech traits for lesion nematode control ...
Cached Biology Technology:Vanda Pharmaceuticals Reports First Quarter 2009 Results 2Vanda Pharmaceuticals Reports First Quarter 2009 Results 3Vanda Pharmaceuticals Reports First Quarter 2009 Results 4Vanda Pharmaceuticals Reports First Quarter 2009 Results 5Vanda Pharmaceuticals Reports First Quarter 2009 Results 6Vanda Pharmaceuticals Reports First Quarter 2009 Results 7Vanda Pharmaceuticals Reports First Quarter 2009 Results 8Vanda Pharmaceuticals Reports First Quarter 2009 Results 9Vanda Pharmaceuticals Reports First Quarter 2009 Results 10LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record 2Divergence Receives $1.2 Million in Grants, Including NSF Grant to Fund Continuing Nematode Research in Corn 2Divergence Receives $1.2 Million in Grants, Including NSF Grant to Fund Continuing Nematode Research in Corn 3
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
(Date:2/5/2015)... 26, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... http://www.nxt-id.com/ ) as part of its 2015 marketing and ... launched its new consumer website for Wocketwallet.com earlier this ... of NXT-ID said, "Our new corporate website naturally showcases ...
(Date:2/5/2015)... Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... RedChip Global Online CEO Conference on January 29 th ... Gino Pereira , CEO of NXT-ID will present and ... the Wocket smart wallet and its full suite of ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3
... has been discovered by a research group at the Sahlgrenska ... an insidious form of glandular cancer usually in the head ... discovery could lead to quicker and better diagnosis and more ... prestigious scientific journal Proceedings of the National Academy of ...
... animals and plants developed different genetic programs for cell ... one at the Swedish University of Agricultural Sciences, has ... programmed cell death in plants and animals are actually ... The findings were published in Nature Cell Biology ...
... in electronics applications, Kansas State University engineers made a ... Berry is a K-State assistant professor of chemical engineering ... single atom thick and discovered just five years ago. ... electronics properties -- Berry and Kabeer Jasuja, a K-State ...
Cached Biology News:New cancer gene discovered 2Cell death occurs in the same way in plants, animals and humans 224-carat gold 'snowflakes' improve graphene's electrical properties 2
St. Louis encephalitis Immunogen: St. Louis encephalitis. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse Anti-Gemin2...
5-bromo-2'-deoxyuridine (BrdU) Cell Biology Cell Proliferation Bromodeoxyuridine (BrdU) and Related Products...
Rat CINC-2 alpha/beta Affinity Purified Polyclonal Ab...
Biology Products: